维莫德吉对上肢局部晚期基底细胞癌的非手术治疗
Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib.
作者信息
Swisher Austin R, Landau Mark J, Davila Allison B, Davila Armando A, Zagaynov Caryn, Bobbitt Christopher A, Leong Darren S, Chang Alexander Y, Chang Walter T
机构信息
Department of Surgery, University of California Riverside School of Medicine, Riverside, USA.
Department of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, USA.
出版信息
Cureus. 2022 Aug 27;14(8):e28479. doi: 10.7759/cureus.28479. eCollection 2022 Aug.
Basal cell carcinoma (BCC) is a common skin malignancy that can present reconstructive challenges in patients with locally advanced diseases of the extremities. This article highlights three cases of locally advanced BCC of the extremities managed with vismodegib (Erivedge, Genentech). Vismodegib is a sonic hedgehog pathway (Shh) inhibitor approved by the FDA for use in metastatic or recurrent BCC. All three patients in our case series demonstrated significant clinical responses with reductions in tumor size which obviated the need for complex reconstructive surgery or amputation.
基底细胞癌（BCC）是一种常见的皮肤恶性肿瘤，对于患有四肢局部晚期疾病的患者而言，可能会带来重建方面的挑战。本文重点介绍了三例使用维莫德吉（Erivedge，基因泰克公司）治疗的四肢局部晚期基底细胞癌病例。维莫德吉是一种经美国食品药品监督管理局（FDA）批准用于转移性或复发性基底细胞癌的音猬因子信号通路（Shh）抑制剂。我们病例系列中的所有三名患者均表现出显著的临床反应，肿瘤大小减小，从而无需进行复杂的重建手术或截肢。
Zotero 插件